Immunology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

The Bloom Infant Probiotic (BIP) Study

This study is testing a probiotic treatment to help improve vaccine responses in infants who received antibiotics early in life. Antibiotics can sometimes disrupt the natural balance of bacteria in the body, which may affect how well vaccines work. If this probiotic proves effective, it could offer a simple way to boost vaccine protection for these infants during their crucial early months.

COVID Protection After Transplant-Immunosuppression Reduction

This trial looked at giving an extra dose of the COVID-19 vaccine to kidney and liver transplant patients, some of whom also had their immune-suppressing medications reduced. Since transplant patients have weaker immune systems, finding ways to increase their protection against COVID-19 is important. The study completed with 48 participants, and results are now available, providing useful information on how best to protect these high-risk groups.

Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector

This early phase study tested a new gene therapy for children with a rare and serious immune disorder called SCID-X1. The therapy aims to restore immune function without the need for chemotherapy or donor cells, which can cause significant side effects. The study has finished enrolling patients, and results are available, offering hope for a gentler treatment option for this condition.

Oral Immunotherapy With Egg in Infants

This trial is exploring whether feeding small, controlled amounts of egg to infants with egg allergies can help them develop tolerance over time. Food allergies can be very challenging for families, and a treatment that helps children outgrow their allergy would be a meaningful advancement. The study plans to follow children over time to see how their allergy status changes.

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

This study is testing a combination of two drugs as a first treatment for chronic graft-versus-host disease, a condition that can occur after a bone marrow transplant. Current treatments are not always effective, so new options are needed. This trial is recruiting patients and aims to see if this drug combination is safe and works well to improve outcomes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.